| Study characteristics |
| Methods |
Randomized, placebo‐controlled |
| Participants |
CABG, valve, combined, aortic or arrhythmia surgery |
| Interventions |
Sotalol vs. placebo |
| Outcomes |
SVA; Mortality; CV Mortality |
| Follow‐Up |
Not reported |
| Concurrent Antiarrhythmic Medications |
None |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Randomization methods not described |
| Allocation concealment (selection bias) |
Unclear risk |
Concealment methods not described |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
No blinding |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
No blinding |
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
"The data from 3 patients were excluded from analysis because of protocol violations (2 patients had taken the trial medication improperly)" |
| Selective reporting (reporting bias) |
Unclear risk |
Protocol not available |
| Intention‐to‐treat analysis |
High risk |
No |
